En Es
Categories

Industry News

Global Sepsis Diagnostics Market Driven by Rising Hospital-Acquired Illnesses

By HospiMedica International staff writers
20 Jun 2022

Image: The global sepsis diagnostics market is expected to reach close to USD 1 billion by 2028 (Photo courtesy of Pexels)

Sepsis is a medical disorder that emerges as a result of the body’s response to infections caused by bacteria, viruses, or fungus. The immune system produces various substances into the bloodstream in this situation, causing hyper inflammation and the production of blood clots. Multiple organ failures, rapid breathing, neurological dysfunction, low blood pressure, and a higher heart rate are all possible complications of sepsis. Molecular diagnosis, biomarkers, flow cytometry, immunoassays, microfluidics, and other processes are used to diagnose sepsis. Hospitals, pathology and reference laboratories, university academic researchers, and other institutions are all using these diagnostic tools. The global sepsis diagnostics market is expected to grow at a CAGR of 8.3% during the period 2022-2028 to reach almost USD 0.88 billion by 2028, driven by a rise in the number of hospital-acquired illnesses and the rapidly growing molecular diagnostics market, although the high cost of automated diagnostic instruments could hamper market growth.


These are the latest findings of ReportLinker (Lyon, France), a provider of market research solutions.


In 2016, the Third International Sepsis Consensus Task Force determined the current criteria for clinical sepsis diagnosis, known as Sequential Organ Failure Assessment (SOFA). This scoring system detects cumulative organ dysfunction as a result of an infection-induced dysregulation of the host’s immune system. Cardiovascular function, respiration, liver function, coagulation, central nervous system function, and renal function are all regarded in the SOFA score. A point is given for each malfunctioning organ system, with a score of 2 points or higher indicating a definite sepsis diagnosis. A high SOFA score is linked to a higher than 10% hospital mortality risk.


SOFA replaces the Systemic Inflammatory Response Syndrome (SIRS) criteria, which was created in 2001. SIRS scoring requires two or more of the following: a temperature of greater than 38°C or less than 36°C, a heart rate of greater than 90 beats per minute, a respiratory rate of greater than 20 beats per minute, or a white blood cell count of greater than 12,000/L or less than 4,000/L. When compared to SIRS and qSOFA, SOFA has higher predictive accuracy. Quick SOFA (qSOFA) is a rapid alternative to SOFA that uses only a subset of the SOFA scoring criteria, such as abnormal mentation, systolic blood pressure under 100 mm Hg, and a breathing rate of 22 or more per minute. qSOFA does not necessitate laboratory testing and can be performed as many times as needed.


The COVID-19 pandemic had a marginally beneficial impact on sales of the sepsis diagnostics market. The widespread COVID-19 pandemic and the emergence of sepsis cases among COVID-19 patients are projected to boost the demand for quick diagnosis, speeding up the use of tools, reagents, and test kits for sepsis detection. Additionally, a rise in the number of hospital-acquired illnesses (HAIs) is expected to drive the growth of the sepsis diagnostics market. HAIs is characterized as nosocomial infections, a prominent cause of morbidity and mortality in hospitals across the world. The most common hospital-acquired illnesses include urinary tract infections, pneumonia, and sepsis. HAIs can induce sepsis in immunocompromised people, the elderly, and people with medical conditions.


Moreover, the rapidly growing molecular diagnostics market will contribute further to the growth of the sepsis diagnostics market. Due to their ease of use and effectiveness in diagnostic procedures, molecular diagnostics has attracted a number of multinational companies and institutes. The gold standard for molecular diagnostic methods has been blood culture analysis for quick and precise infection profiling. Several firms are investing in point-of-care molecular diagnostics to improve patient management and early detection of bacterial and viral infections. However, the high cost of automated diagnostic instruments for diagnosing sepsis is acting as a major impediment to market growth. Companies are focusing on creating automated diagnostic instruments for identifying sepsis based on modern technologies such as molecular diagnostics. However, government hospitals and scientific research laboratories cannot acquire such systems due to budget constraints.


Based on method, the automated segment held the largest revenue share in the sepsis diagnostics market in 2021. The use of billing codes and the installation of predictable evaluation are based on agreement definitions that have been used in efforts to automate sepsis identification. Although billing codes are simple to extract and have a strong positive predictive value (PPV) for sepsis, they typically do not document the onset of sepsis and have low sensitivity when compared to clinician assessment. Changing medical practicing habits and reimbursement policies also have an impact on them. Consensus-based definitions have improved over time and across institutions, but they still rely on doctors to validate if organ dysfunction is attributable to sepsis, resulting in low PPV when automated.


Based on test type, the laboratory tests segment held the largest revenue share in the sepsis diagnostics market in 2021 as laboratory testing is more accurate than POC testing in identifying sepsis. Laboratory testing allows for a comprehensive examination of the pathogen and its medication resistance profile. In addition, routine lactate testing, which is a vague but valuable indication of sepsis, is done efficiently in laboratory settings. The dependence of the public and physicians on these labs has grown dramatically with the introduction of technologically advanced products.


Based on pathogen, the fungal sepsis segment held the largest revenue share in the sepsis diagnostics market in 2021. Fungi are responsible for about 15% of all infections, and invasive fungal infections are becoming a more common cause of sepsis, especially in critically ill patients. This disease is a life-threatening illness that can occur anywhere in the body as a result of an infection. Severe instances of sepsis are frequently caused by infections that spread throughout the body and through the bloodstream. Based on product, the software segment held the largest revenue share in the sepsis diagnostics market in 2021 due to a rise in the implementation of modern software platforms by healthcare professionals for better sepsis detection and management.


Based on end-user, the hospitals and specialty clinics segment held the largest revenue share in the sepsis diagnostics market in 2021, due to the rising number of patients diagnosed with sepsis, and in-house hospital and clinics undertaking a large number of blood culture tests to identify blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses). Based on technology, the blood culture segment held the largest revenue share in the sepsis diagnostics market in 2021. One of the most significant investigations in the treatment of sepsis is blood culture as it enables the identification of the sepsis-causing bacterium, the selection of a relevant empirical and specific antibiotic, and the identification of the infection’s focal location. Moreover, the affordable pricing of microbiological techniques and the widespread usage of blood culture procedures for sepsis diagnosis also contribute to the high revenue share of the blood culture segment in the sepsis diagnostics market.


Geographically, North America held the largest revenue share in the sepsis diagnostics market in 2021 due to a well-established medical devices market and healthcare system, widespread implementation of innovative sepsis diagnosing technologies by health personnel, growing prevalence of HAIs, and adoption of advanced technologies for sepsis diagnosis in the region.


Related Links:
ReportLinker 



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

05 Aug 2022
Bio-Rad Acquires Curiosity Diagnostics from Scope Fluidics
Bio-Rad Laboratories (Hercules, CA, USA) has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (Warsaw, Poland) for a total consideration of up to USD 170 million, consisting of approximately USD 100 million in cash, and up to USD 70 million in future milestone payments.
Read More
04 Aug 2022
Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure
The global capsule endoscopy system market is expanding at a rapid pace due to the rising demand for the procedure using minimally invasive diagnostic techniques, increase in the introduction of technologically advanced capsules, growth in the geriatric population, and rising prevalence of cancer around the world.
Read More
02 Aug 2022
PerkinElmer Divests Other Businesses to Focus on Life Sciences and Diagnostics
PerkinElmer, Inc. (Waltham, MA; USA) has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital (New York, NY, USA) for total consideration of USD 2.45 billion in cash.
Read More
31 Jul 2022
Labcorp to Spin Off Clinical Development Business
LabCorp Diagnostics (Burlington, NC, USA) has announced that its board of directors has authorized the company to pursue a spin-off of its wholly owned Clinical Development business to shareholders through a tax-free transaction.
Read More
31 Jul 2022
IFCC Celebrates 70 Years of Advancing Science of Laboratory Medicine and In Vitro Diagnostics
The IFCC is celebrating 70 years (1952 – 2022) of enormous achievements that have been extraordinary and impressive, contributing to its mission of “Advancing excellence in laboratory medicine for better healthcare worldwide”.
Read More
27 Jul 2022
Medlab Asia and Asia Health to Host First-Ever Live, In-Person Event in Thailand
Informa Markets (London, UK), in partnership with Impact Muang Thong Thani (Nonthaburi, Thailand), have confirmed that Medlab Asia and Asia Health will take place in Thailand for the first time when the co-located events return live and in-person at the Impact Exhibition Center, Bangkok, from 19-21 October 2022.
Read More
25 Jul 2022
Registration Opens for RSNA 2022
Registration is now open for the Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) 108th Scientific Assembly and Annual Meeting to be held at McCormick Place Chicago, Nov. 27 – Dec. 1, 2022.
Read More
25 Jul 2022
Bioperfectus and ELITechGroup Collaborate for Monkeypox Virus Testing Across Europe
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) and ELITechGroup S.p.A. (Puteaux, France) have entered into a strategic partnership for monkeypox virus testing across Europe.
Read More
20 Jul 2022
GE's Healthcare Business to Be Named GE HealthCare
GE (Boston, MA, USA) has announced that GE HealthCare will be the name of its healthcare business following its planned separation into three industry-leading, global, investment-grade public companies.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions